In this episode of Moving Medicine Forward, we sit down with Dr. Helio Tedesco, a globally recognized transplant nephrologist from São Paulo, Brazil, who leads one of the world’s largest kidney transplant programs. Joined by CTI’s Dr. Christopher Boshkos and clinical scientist Erika Aldag, the conversation explores the challenges and innovations behind managing over 15,000 transplant patients, from telehealth expansion and donor matching to cutting-edge immunosuppressive strategies and the future of surveillance tools like cell-free DNA and the iBox model. This episode offers a rare look into the science, systems, and human dedication driving transplant care forward.00:00 – IntroductionHost Jeremy Strand introduces the podcast and this episode’s focus on transplant innovation. 00:35 – Meet the GuestsDr. Helio Tedesco (São Paulo), Dr. Christopher Boshkos, and clinical scientist Erika Aldag join to discuss global kidney transplant practices. 01:13 – Dr. Tedesco’s BackgroundNearly 40 years in nephrology, performing 1,000+ kidney transplants yearly, with a strong research background. 03:17 – Managing Large Transplant PopulationsInsights into follow-up care, decentralized nephrologist networks, and expanding telehealth use. 06:30 – Risk Stratification & ImmunosuppressionHow patients are matched to regimens, minimizing rejection and addressing regional challenges. 11:49 – Innovations in Induction TherapyDr. Tedesco explains their one-dose thymoglobulin approach and its benefits over traditional multi-dose methods. 18:34 – New Tools for Monitoring Graft HealthUse of donor-derived cell-free DNA, biopsy techniques, and barriers to widespread adoption. 24:25 – The iBox ModelDiscussion on the potential of iBox as a predictive tool for clinical trials and long-term graft survival. 28:15 – Where Transplant Science Is HeadedCalls for better long-term therapies, biologics, and more patient-friendly immunosuppression options. 32:15 – Telehealth and Outpatient ManagementSuccesses and learnings from scaling telehealth to support a large patient base. 37:41 – Closing RemarksAppreciation for the collaboration between CTI and global transplant 

Elizabeth Doughman, editor, WATT PoultryUSA and Poultry Future, and Chris Greene, national account manager, farm and ranch, Central Life Sciences, talk about how fly control and biosecurity impact poultry health and egg production.

Send us a textWelcome back Rounds Table Listeners! Today we're introducing a new format—the first episode in our Clinical Practice Guidelines series. This week, Drs. Mike and John Fralick discuss the 2025 ACC/AHA Clinical Practice Guidelines for Acute Coronary Syndrome. Here we go!2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (0:00 - 18:56)Mike's interview with Dr. Jeff Carson:Episode 110 - Restrictive versus Liberal Transfusion in Myocardial Infarction with Dr. Jeff CarsonThe Good Stuff:Egg cracking tips! (18:57 - 19:47)Jerro (19:48 - 20:47)Questions? Comments? Feedback? We’d love to hear from you! @roundstable @InternAtWork @MedicinePods

As we continue our look at Cybersecurity in MedicalDevices,  this episode focused on the growing impact of cybersecurity on patient safety. Scott Mattila, COO of Intraprise Health, discusses how cybersecurity directly affects patient safety, the importance of cybersecurity by design, and risk mitigation strategies to protect patients from harm.

Note: This episode includes discussions on sexual harassment.Join Rori and Emilia as they discuss key insights from their interview with Dr. Pilar Ossorio. They focus on her strategies for dealing with harassment and her bold career change from molecular biology to bioethics. Pilar's proactive approach to harassment and her career shift offer key lessons. They also discuss her important work on race and ethnicity in scientific research, showing how these categories can vary depending on context.EPISODE CHAPTERS:00:32 Confronting Harassment: Dr. Pilar Ossorio's Strategy03:07 Lessons on Handling Harassment04:12 Embracing Change in Career Paths05:45 Dr. Ossorio's Work on Race and Ethnicity in ScienceCREDITS: This episode is produced and edited by Maribel Quezada Smith. Production Coordinator, Marissa Alcantar. A Diferente Creative Production. Special thanks to Dr. Pilar Ossorio

In this illuminating episode of Research Renaissance, host Deborah Westphal sits down with Ana Maiques, CEO and co-founder of Neuroelectrics, a groundbreaking company at the forefront of non-invasive brain stimulation technology. Together, they explore the intersection of neuroscience, entrepreneurship, and innovation, diving deep into how electrical brain stimulation is changing the future of treatment for neurological disorders like epilepsy, depression, and Alzheimer’s.Ana shares her unconventional journey into entrepreneurship, her commitment to ethical tech, and the long road to FDA approval. She also discusses the development of Neuroelectrics’ personalized brain therapies and the potential for at-home use of medical-grade neurostimulation devices.📌 Resources & Mentions:NeuroelectricsKaren Toffler Charitable TrustThe Termeer FoundationAI and Neuroethics Summit with President MacronBrain Digital Twin / Neurotwin platform📫 Stay ConnectedConnect with Ana Maiques: 📧 ana.maiques@neuroelectrics.com 🔗 LinkedIn – NeuroelectricsFollow Research Renaissance: 🌐 tofflertrust.org 🎧 Subscribe on your favorite podcast platform 📞 Contact us with ideas or questions!To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

Send us a text"Is your pancreas suddenly malfunctioning, or could it be your antidepressant?" That's the question at the heart of this explosive episode where we reveal the shocking disconnect between existing research and what medical providers tell patients about SSRI side effects.When co-host Jen called her doctor about concerning blood glucose results during her Lexapro taper, she was immediately shut down with "No, that can't be related to your medication." But as we uncover, multiple studies dating back over a decade have established clear connections between SSRIs and metabolic disturbances. We share a jaw-dropping recording of this medical gaslighting in action, breaking down all the ways Jen's legitimate concerns were dismissed without consideration.Looking deeper, we explore compelling research including a 2013 study showing significant increases in weight, blood glucose, cholesterol, and triglycerides in women taking various SSRIs for just 16 weeks. Even more convincingly, a massive 2020 Japanese study of 90,000 participants concluded that "antidepressants increased the risk of type 2 diabetes," with risk increasing alongside duration and dosage of medication use. Perhaps most importantly, both studies found these metabolic markers returned to baseline after discontinuation - exactly what many patients report but are told is impossible.This episode serves as both validation for those who've felt dismissed by healthcare providers and as ammunition for your next medical appointment. We discuss strategies for advocating for yourself, monitoring your own health metrics, and navigating a system that often refuses to acknowledge medication side effects. If you've ever wondered whether your changing health status might be connected to your psychiatric medication, this conversation will equip you with knowledge to push back against medical gaslighting and take control of your health journey. Support the showAre you tired of being gaslit and want to DEEP THROAT some more truth? We want to hear from you! Message us your gaslit stories at thegaslittruthpodcast@gmail.com While you are at it, Follow us on Instagram, Facebook and YouTube @thegaslittruthpodcast. Be sure to Hit that subscribe button and get alerts for more episodes! Thanks for listening!Follow Us individually at Dr. Teralyn: Instagram @Dr_Teralyn Facebook @DrTeralyn Tik Tok @Dr_Teralyn Therapist Jenn: Instagram @TherapistJen TikTok @Jenn.Schmitz

In this Performing Arts SIG panel, PASIG Vice President of Education Melissa Kolski, PT, leads an expert discussion featuring a lineup of clinicians deeply embedded in the world of circus and performing arts: Heather Heineman, PT, DPT, OCS, WCS; Emily Scherb, PT, DPT (author of Aerial Athletes: Flying, Hanging, Wrapping, Catching); and Dawn Muci, DPT, SCS, ATC. Together, they explore physical therapy care for circus artists through the lens of orthopaedics, performance demands, and patient individuality.Join the PASIG: https://www.orthopt.org/content/special-interest-groups/performing-artsTarget Audience:orthopaedic physical therapists, performing arts PTs, PT students, clinicians treating hypermobility, circus or dance artists, and anyone managing complex athletic performers.

Welcome back to the Pharmaverse!In this episode our host Michael Pietrack speaks with Isaac Veinbergs, co-founder and chief business officer of Libra Therapeutics. They discuss the company's focus on developing therapeutics for neurodegenerative diseases through the mechanism of autophagy. Isaac shares insights from his career journey, including pivotal moments that shaped his path from academia to biotech. Listen to Veinbergs "We're working on therapeutics for neurological diseases." The conversation also delves into the current fundraising landscape in the pharmaceutical industry, investor hesitancy, and the importance of flexibility and humility in leadership. "If you do the right science, things will all work out fine." Tune in for a great conversation about leadership, neurodegenerative treatments, pivots in Pharma and more! Takeaways🧠 Libra Therapeutics focuses on therapeutics for neurological diseases.💡 Isaac's passion for biotech stems from personal family experiences with dementia.🔄 Transitioning from academia to biotech can be met with skepticism.🎯 Identifying and seizing opportunities is crucial for career advancement.📉 The current fundraising environment is challenging for many biotech companies.📊 Investor hesitancy is influenced by market conditions and lack of recent IPOs.📖 A compelling scientific story can attract investment, even for first-time founders.🗣️ Effective management requires clear communication and goal setting.🌊 Flexibility in leadership is essential to adapt to changing company needs.🙇 Humility is important when transitioning roles within a company.Chapters00:00Introduction to Libra Therapeutics and Its Mission02:58Career Development and Key Pivot Points06:04Transitioning from Science to Business Development09:10Fundraising Landscape in the Pharmaceutical Industry12:14Investor Hesitancy and Optimism14:59Leadership Insights and Flexibility18:07The Importance of Team Dynamics and Humility

In this week's episode, we talk about vascular dementia, a significant yet often overlooked brain disorder caused by reduced blood flow, usually due to stroke and/or vascular disease. It accounts for 15-20% of dementia cases and leads to cognitive decline, memory loss, and motor impairments. While no cure exists, prevention is key—controlling risk factors like high blood pressure, diabetes, and smoking can significantly reduce the likelihood of developing the disease. Research suggests that physical fitness offers strong protective benefits, and some Alzheimer’s medications may provide limited relief. Continued clinical trials are essential in the search for effective treatments, emphasizing the need for more participation in medical research to safeguard brain health. Listen to learn all about vascular dementia.